Benchmark lowered the firm’s price target on Cardio Diagnostics to $1.35 from $4 and keeps a Speculative Buy rating on the shares, noting that the company ended Q4 with $1.3M in cash and added about $1.9M in new capital during Q1. The firm’s new price target is based on a 2028 revenue estimate of $27M, discounted to the end of 2024 at 20%, though it says there could be upside if the revenue ramps more quickly than the firm anticipates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDIO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue